BACKGROUND: It has been proposed that ligation of CD80 and CD86 induces reverse signaling into antigen-presenting cells. In this study, we tested the ability of abatacept, a soluble human fusion protein comprising the extracellular domain of cytotoxic T lymphocyte antigen 4 and a fragment of the Fc domain of IgG(1), to activate antigen-presenting cells by measuring changes in global transcriptional responses. METHODS: Affymetrix chips were used to measure gene expression levels using mRNA isolated from immature and mature human dendritic cells and a B cell line following 6 h of treatment with abatacept. RESULTS: In contrast to robust transcriptional responses induced by the control treatment phorbol-12-myristate-13-acetate, abatacept induced minimal gene changes in three different populations of antigen-presenting cells. Furthermore, no gene changes were observed in response to belatacept, a modified version of abatacept that binds with higher avidity to CD80 and CD86. CONCLUSIONS: We conclude that reverse signaling in antigen-presenting cells is unlikely to occur in response to either abatacept or belatacept, thereby supporting the modulation of CD28 signaling on T cells as the main mechanism of action for these therapeutics.
BACKGROUND: It has been proposed that ligation of CD80 and CD86 induces reverse signaling into antigen-presenting cells. In this study, we tested the ability of abatacept, a soluble human fusion protein comprising the extracellular domain of cytotoxic T lymphocyte antigen 4 and a fragment of the Fc domain of IgG(1), to activate antigen-presenting cells by measuring changes in global transcriptional responses. METHODS: Affymetrix chips were used to measure gene expression levels using mRNA isolated from immature and mature human dendritic cells and a B cell line following 6 h of treatment with abatacept. RESULTS: In contrast to robust transcriptional responses induced by the control treatment phorbol-12-myristate-13-acetate, abatacept induced minimal gene changes in three different populations of antigen-presenting cells. Furthermore, no gene changes were observed in response to belatacept, a modified version of abatacept that binds with higher avidity to CD80 and CD86. CONCLUSIONS: We conclude that reverse signaling in antigen-presenting cells is unlikely to occur in response to either abatacept or belatacept, thereby supporting the modulation of CD28 signaling on T cells as the main mechanism of action for these therapeutics.
Authors: C B Thompson; T Lindsten; J A Ledbetter; S L Kunkel; H A Young; S G Emerson; J M Leiden; C H June Journal: Proc Natl Acad Sci U S A Date: 1989-02 Impact factor: 11.205
Authors: Joel M Kremer; Maxime Dougados; Paul Emery; Patrick Durez; Jean Sibilia; William Shergy; Serge Steinfeld; Elizabeth Tindall; Jean-Claude Becker; Tracy Li; Isaac F Nuamah; Richard Aranda; Larry W Moreland Journal: Arthritis Rheum Date: 2005-08
Authors: T Lindsten; K P Lee; E S Harris; B Petryniak; N Craighead; P J Reynolds; D B Lombard; G J Freeman; L M Nadler; G S Gray Journal: J Immunol Date: 1993-10-01 Impact factor: 5.422
Authors: Adriano Boasso; Jean-Philippe Herbeuval; Andrew W Hardy; Christiana Winkler; Gene M Shearer Journal: Blood Date: 2004-10-05 Impact factor: 22.113
Authors: Edda Mayer; Markus Hölzl; Sarah Ahmadi; Barbara Dillinger; Nina Pilat; Dietmar Fuchs; Thomas Wekerle; Andreas Heitger Journal: Int Immunopharmacol Date: 2013-02-20 Impact factor: 4.932